Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice-Reference-Cited by-同舟云学术

Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice

Published:2023-01-26 Issue:3 Volume:66 Page:1928-1940
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Faber Erik B.¹²^ORCID,Wang Nan¹^ORCID,John Kristen¹^ORCID,Sun Luxin³^ORCID,Wong Henry L.¹^ORCID,Burban David⁴^ORCID,Francis Rawle¹,Tian Defeng¹^ORCID,Hong Kwon H.¹,Yang An¹,Wang Liming¹^ORCID,Elsaid Mazen¹,Khalid Hira¹,Levinson Nicholas M.⁴^ORCID,Schönbrunn Ernst³^ORCID,Hawkinson Jon E.¹^ORCID,Georg Gunda I.¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota College of Pharmacy─Twin Cities, Minneapolis, Minnesota55414, United States

2. Medical Scientist Training Program, University of Minnesota Medical School─Twin Cities, Minneapolis, Minnesota55455, United States

3. Drug Discovery Department, Moffitt Cancer Center, Tampa, Florida33612, United States

4. Department of Pharmacology, University of Minnesota Medical School─Twin Cities, Minneapolis, Minnesota55455, United States

Funder

National Cancer Institute

NIH Office of the Director

National Institute of General Medical Sciences

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine